Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
TORONTO, Aug. 21, 2023 /PRNewswire/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group.
多倫多，2023年8月21日/美通社/--安提貝治療公司(多倫多證券交易所代碼：ATE)首席執行官兼董事首席執行官丹·萊戈特在採訪與TMX集團合作。
The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View From The C-Suite visit
來自C-Suite系列視頻採訪的觀點突出了多倫多證券交易所和多倫多證券交易所創業板上市公司的獨特視角。通過視頻，您可以深入瞭解公司高管在當前商業環境中的想法。要查看C-Suite的最新視圖，請訪問
About Antibe Therapeutics (TSX: ATE)
關於安替比治療公司(多倫多證券交易所市場代碼：ATE)
Antibe Therapeutics is a clinical-stage biotech company developing next-generation, safer medicines for pain and inflammation. The company's proprietary drug platform is designed to overcome the gastrointestinal ulcers and bleeding associated with NSAIDs, a class of drugs used by most North Americans and by billions of people globally.
安提貝治療公司是一家臨床階段的生物技術公司，開發下一代更安全的疼痛和炎症藥物。該公司的專利藥物平臺旨在克服與非類固醇抗炎藥相關的胃腸道潰瘍和出血，非類固醇抗炎藥是大多數北美人和全球數十億人使用的一類藥物。
CNW sponsored announcement. To learn more visit .
CNW贊助的公告。要了解更多資訊，請訪問。
SOURCE Toronto Stock Exchange
來源：多倫多證券交易所